Jennifer Brogdon - 2021 World Medical Innovation Forum
May 2–4, 2022
Jennifer Brogdon
This speaker appears at this event:

This speaker appears in these events:

Jennifer Brogdon

Executive Director, Head of Cell Therapy Research, Exploratory Immuno-Oncology, NIBR

Jennifer Brogdon, PhD is currently Executive Director, Head of Cell Therapy Research, in the Department of Exploratory Immuno-Oncology of Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA. Jennifer leads a diverse, cross-functional team to develop next generation CAR-T cell therapies for Oncology and is responsible for driving innovation, strategy and building a therapeutic pipeline from target discovery to first in human (FIH) clinical studies. Since she joined NIBR in 2004, Jennifer has developed broad expertise in antibody, small molecule and cell & gene therapy programs, with one of her most notable contributions during the BLA submission, ODAC and approval of Kymriah. In 2018, she received the Novartis Distinguished Scientist Award for her contributions in the CAR-T cell collaboration with the University of Pennsylvania to treat pediatric ALL patients and to innovate novel therapies for multiple hematological and solid malignancies.
Her drug discovery experience includes >14 distinct therapeutic immuno-oncology programs (antibody, therapeutic protein and >9 novel CAR-T cell therapies) which have reached Phase I/II clinical trials. In addition, Jennifer sits on several internal, cross-divisional leadership teams and joint steering committees with external partners, while also contributing regularly to BD&L opportunities. She holds a PhD in Immunology from Duke University and a postdoctoral fellowship in Immunobiology from Yale University.

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA